



ASX ANNOUNCEMENT

3 April 2025

Entitlement Offer closing date extended to 22 April 2025

Melbourne, Australia, 3 April 2025: Chimeric Therapeutics Limited (ASX:CHM) (**Chimeric or Company**) refers to the non-renounceable entitlement offer announced on 18 March 2025 (**Offer**).

The Company advises that the Closing Date for the Offer has been extended to 5.00 pm (Sydney time) on Tuesday, 22 April 2025. The revised indicative timetable for the Offer is set out below.

Key dates¹

Event	Date
Offer closes (5.00 pm, Sydney time) (Closing Date)	22 April 2025
New Shares quoted on a deferred settlement basis	23 April 2025
Announcement of results of the Offer	24 April 2025
Allotment of New Shares and New Options issued under the Offer	30 April 2025
Despatch of holding statements for New Shares and New Options issued under the Offer	30 April 2025

How to Participate

The Prospectus and your Personalised Entitlement and Acceptance Form were mailed or emailed (depending on your communication preference) on 25 March 2025 and can be accessed at: <https://www.investorserve.com.au/>. The Prospectus can also be accessed via the Company's website <https://chimerictherapeutics.com/>.

The number of Shares for which you are entitled to apply for under the Offer (Entitlement) is shown on your Personalised Entitlement and Acceptance Form.

Any Shares not taken up by the Closing Date may be made available to those Eligible Shareholders who took up their full Entitlement and applied for additional New Shares under the Top Up Facility.

¹All dates are indicative only and subject to change. Chimeric reserves the right to withdraw or vary the timetable without notice.



Applications

To access the online system at www.investorserve.com.au, you will need to provide your Securityholder Reference Number (SRN) or Holder Identification Number (HIN) and postcode and follow the instructions provided including making payment by BPAY® for the securities you wish to subscribe for.

If you are unable to access www.investorserve.com.au, please contact the Company's share registry on 1300 737 760 (in Australia) or +61 2 9290 9600 (outside Australia).

Actions required by Eligible Shareholders

There are a number of actions you may take:

- accept your full Entitlement;
- accept your full Entitlement and apply for additional securities as part of the Top Up Facility;
- accept part of your Entitlement; or
- if you do not wish to accept all or part of your Entitlement, you are not obliged to do anything.

You should read the entire Prospectus carefully and seek professional advice before deciding whether to invest in the Offer.

If you have any queries, please do not hesitate to contact Boardroom Pty Ltd, on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia) between 8.30 am and 5.00 pm (AEDT) Monday to Friday during the offer period or, alternatively, consult your professional adviser.

About Chimeric

Chimeric, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR-T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR-T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute



at Penn. Preclinical evidence for CDH17 CAR-T was published by Dr. Hua and colleagues in 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR-T therapy developed for the treatment of patients with solid tumours. CLTX CAR-T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Executive Chairman Paul Hopper.

For further information, please contact:

If you have questions about the Entitlement Offer, please contact the share registry, Boardroom Pty Ltd on 1300 737 760 (inside Australia) or +61 2 9290 9600 (outside Australia).

Important information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to in this document have not been and will not be registered under the United States Securities Act of 1933 (the 'US Securities Act'), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.

This document may not be distributed or released in the United States.

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. Chimeric does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.